Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.

Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ

Obesity (Silver Spring, Md.)21 Jan 2010Cited by 65 (Europe PMC)

PMID20094043DOI10.1038/oby.2009.478PepBankPUB-20094043

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

01HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In overweight or obese adults without diabetes, week 24 weight change was reported as -3.7% with pramlintide alone and -2.2% with placebo.
In plain wordsIn adults with overweight or obesity, weight change at 24 weeks was reported as -3.7% with pramlintide alone and -2.2% with placebo.
Peptide
Pramlintide (Symlin)
Outcome
Direction not reportedBody weight change at week 24 with pramlintide alone
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
−3.7%
pramlintide alone
Weight change
−2.2%
placebo
Source sentences
Summary
Weight loss achieved at week 24 with either combination treatment was greater than with pramlintide alone or placebo (P < 0.001; 11.1 +/- 1.1% with pramlintide + sibutramine, 11.3 +/- 0.9% with pramlintide + phentermine, -3.7 +/- 0.7% with pramlintide; -2.2 +/- 0.7% with placebo; mean +/- s.e.).
1 context sentence(design, population, supporting numbers)
Summary · context
received placebo subcutaneously (sc) t.i.d., pramlintide sc (120 microg t.i.d.), pramlintide sc (120 microg t.i.d.) + oral sibutramine (10 mg q.a.m.), or pramlintide sc (120 microg t.i.d.) + oral phentermine (37.5 mg q.a.m.) for 24 weeks.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2009404301
02HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In overweight or obese adults, pramlintide plus sibutramine produced greater weight loss than pramlintide alone.
In plain wordsIn overweight or obese adults, pramlintide plus sibutramine produced greater weight loss than pramlintide alone.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseWeight loss with sibutramine combination versus pramlintide
Study
n: not reported in source
Comparator
Pramlintide alone
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
11.1%
pramlintide + sibutramine
Weight change
−3.7%
pramlintide alone
Source sentences
Summary
Weight loss achieved at week 24 with either combination treatment was greater than with pramlintide alone or placebo (P < 0.001; 11.1 +/- 1.1% with pramlintide + sibutramine, 11.3 +/- 0.9% with pramlintide + phentermine, -3.7 +/- 0.7% with pramlintide; -2.2 +/- 0.7% with placebo; mean +/- s.e.).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine.
Summary · context
All patients also received lifestyle intervention.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2009404302
03HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In overweight or obese adults, pramlintide plus sibutramine produced greater weight loss than placebo.
In plain wordsIn overweight or obese adults, pramlintide plus sibutramine produced greater weight loss than placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseWeight loss with sibutramine combination versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
11.1%
pramlintide + sibutramine
Weight change
−2.2%
placebo
Source sentences
Summary
Weight loss achieved at week 24 with either combination treatment was greater than with pramlintide alone or placebo (P < 0.001; 11.1 +/- 1.1% with pramlintide + sibutramine, 11.3 +/- 0.9% with pramlintide + phentermine, -3.7 +/- 0.7% with pramlintide; -2.2 +/- 0.7% with placebo; mean +/- s.e.).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine.
Summary · context
All patients also received lifestyle intervention.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2009404303
04HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In overweight or obese adults, pramlintide plus phentermine produced greater weight loss than pramlintide alone.
In plain wordsIn overweight or obese adults, pramlintide plus phentermine produced greater weight loss than pramlintide alone.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseWeight loss with phentermine combination versus pramlintide
Study
n: not reported in source
Comparator
Pramlintide alone
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
11.3%
pramlintide + phentermine
Weight change
−3.7%
pramlintide alone
Source sentences
Summary
Weight loss achieved at week 24 with either combination treatment was greater than with pramlintide alone or placebo (P < 0.001; 11.1 +/- 1.1% with pramlintide + sibutramine, 11.3 +/- 0.9% with pramlintide + phentermine, -3.7 +/- 0.7% with pramlintide; -2.2 +/- 0.7% with placebo; mean +/- s.e.).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine.
Summary · context
All patients also received lifestyle intervention.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2009404304
05HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialEfficacy outcome
In overweight or obese adults, pramlintide plus phentermine produced greater weight loss than placebo.
In plain wordsIn overweight or obese adults, pramlintide plus phentermine produced greater weight loss than placebo.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseWeight loss with phentermine combination versus placebo
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
Weight loss
11.3%
pramlintide + phentermine
Weight change
−2.2%
placebo
Source sentences
Summary
Weight loss achieved at week 24 with either combination treatment was greater than with pramlintide alone or placebo (P < 0.001; 11.1 +/- 1.1% with pramlintide + sibutramine, 11.3 +/- 0.9% with pramlintide + phentermine, -3.7 +/- 0.7% with pramlintide; -2.2 +/- 0.7% with placebo; mean +/- s.e.).
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine.
Summary · context
All patients also received lifestyle intervention.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2009404305
06HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome
In overweight or obese adults, pramlintide plus sibutramine increased heart rate from baseline.
In plain wordsIn overweight or obese adults, pramlintide plus sibutramine increased heart rate from baseline.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseHeart rate with sibutramine combination
Study
n: not reported in source
Outcome group
Adverse events · Cardiovascular
Measurements
Heart rate change
3.1 beats/min
pramlintide plus sibutramine
Source sentences
Summary
Elevations from baseline in heart rate and diastolic blood pressure were demonstrated with both pramlintide + sibutramine (3.1 +/- 1.2 beats/min, P < 0.05; 2.7 +/- 0.9 mm Hg, P < 0.01) and pramlintide + phentermine (4.5 +/- 1.3 beats/min, P < 0.01; 3.5 +/- 1.2 mm Hg, P < 0.001) using 24-h ambulatory monitoring.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine.
Summary · context
All patients also received lifestyle intervention.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2009404306
07HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome
In overweight or obese adults, pramlintide plus sibutramine increased diastolic blood pressure from baseline.
In plain wordsIn overweight or obese adults, pramlintide plus sibutramine increased diastolic blood pressure from baseline.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseDiastolic blood pressure with sibutramine combination
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Measurements
Diastolic blood pressure change
2.7 mm Hg
pramlintide plus sibutramine
Source sentences
Summary
Elevations from baseline in heart rate and diastolic blood pressure were demonstrated with both pramlintide + sibutramine (3.1 +/- 1.2 beats/min, P < 0.05; 2.7 +/- 0.9 mm Hg, P < 0.01) and pramlintide + phentermine (4.5 +/- 1.3 beats/min, P < 0.01; 3.5 +/- 1.2 mm Hg, P < 0.001) using 24-h ambulatory monitoring.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine.
Summary · context
All patients also received lifestyle intervention.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2009404307
08HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome
In overweight or obese adults, pramlintide plus phentermine increased heart rate from baseline.
In plain wordsIn overweight or obese adults, pramlintide plus phentermine increased heart rate from baseline.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseHeart rate with phentermine combination
Study
n: not reported in source
Outcome group
Adverse events · Cardiovascular
Measurements
Heart rate change
4.5 beats/min
pramlintide plus phentermine
Source sentences
Summary
Elevations from baseline in heart rate and diastolic blood pressure were demonstrated with both pramlintide + sibutramine (3.1 +/- 1.2 beats/min, P < 0.05; 2.7 +/- 0.9 mm Hg, P < 0.01) and pramlintide + phentermine (4.5 +/- 1.3 beats/min, P < 0.01; 3.5 +/- 1.2 mm Hg, P < 0.001) using 24-h ambulatory monitoring.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine.
Summary · context
All patients also received lifestyle intervention.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2009404308
09HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome
In overweight or obese adults, pramlintide plus phentermine increased diastolic blood pressure from baseline.
In plain wordsIn overweight or obese adults, pramlintide plus phentermine increased diastolic blood pressure from baseline.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseDiastolic blood pressure with phentermine combination
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Measurements
Diastolic blood pressure change
3.5 mm Hg
pramlintide plus phentermine
Source sentences
Summary
Elevations from baseline in heart rate and diastolic blood pressure were demonstrated with both pramlintide + sibutramine (3.1 +/- 1.2 beats/min, P < 0.05; 2.7 +/- 0.9 mm Hg, P < 0.01) and pramlintide + phentermine (4.5 +/- 1.3 beats/min, P < 0.01; 3.5 +/- 1.2 mm Hg, P < 0.001) using 24-h ambulatory monitoring.
2 context sentences(design, population, supporting numbers)
Summary · context
This randomized placebo-controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine.
Summary · context
All patients also received lifestyle intervention.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2009404309
10HumanNot a test of Pramlintide (Symlin) aloneRandomized controlled trialSafety outcome
In overweight or obese adults, most recipients of pramlintide-containing combinations remained within normal blood pressure ranges.
In plain wordsIn overweight or obese adults, most recipients of pramlintide-containing combinations kept blood pressure within normal ranges.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableNormal blood pressure ranges
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
However, the majority of subjects receiving these treatments remained within normal blood pressure ranges.
3 context sentences(design, population, supporting numbers)
Summary · context
Elevations from baseline in heart rate and diastolic blood pressure were demonstrated with both pramlintide + sibutramine (3.1 +/- 1.2 beats/min, P < 0.05; 2.7 +/- 0.9 mm Hg, P < 0.01) and pramlintide + phentermine (4.5 +/- 1.3 beats/min, P < 0.01; 3.5 +/- 1.2 mm Hg, P < 0.001) using 24-h ambulatory monitoring.
Summary · context
This randomized placebo-controlled trial examined the safety and efficacy of the amylin analogue pramlintide alone or in combination with either phentermine or sibutramine.
Summary · context
All patients also received lifestyle intervention.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-2009404310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.